SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is receiving significant attention following the announcement of a $3 billion convertible note offering and a 35 million share at-the-market (ATM) program, moves that triggered a sharp sell-off as traders voiced frustration over dilution. Despite the negative market reaction to the financing, discussion remains anchored by the company's recent operational updates, including the deployment of a multi-rack Nvidia Vera Rubin cluster and reports of high-priced customer compute contracts.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

Markets are showing resilience, with indices rebounding in overnight trading following a 25-basis-point Federal Reserve rate hike that market participants largely anticipated. While many traders remain focused on potential future hikes and macroeconomic headwinds, the immediate conversation is driven by the market's recovery and intense debate over whether current price action represents a genuine relief rally or a trap for bears.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is experiencing a relief rally as investors digest the Federal Reserve's decision to hike interest rates by 25 basis points, with many traders viewing the move as already priced into the market. While some participants express caution over a "higher-for-longer" interest rate outlook and macroeconomic headwinds, bullish sentiment persists as many investors emphasize buying the dip and anticipate a continued upward trend in AI-driven tech stocks.

Fluence Energy, Inc. engages in energy storage products and services, and artificial intelligence-enabled digital applications for renewables and storage. Its storage includes Smartstack, Gridstack Pro, Grisdtack, and Ultrastack. The company was founded on June 21, 2021, and is headquartered in Arlington, VA.

Fluence Energy Inc - Ordinary Shares - Class A

Fluence Energy shares are experiencing extreme volatility, recovering sharply after an initial sell-off sparked by a second consecutive fiscal 2026 guidance cut and wider-than-expected EBITDA losses. While the company attributed the revision to persistent production delays at its Houston manufacturing facility, retail traders are debating whether the stock represents a deep-value buying opportunity given strong long-term demand and backlog, or if execution failures and management's guidance credibility warrant further downside.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD shares are rebounding as investors dismiss recent speculation about a potential slowdown in AI capital spending as political narrative rather than a shift in fundamental demand. The conversation remains volatile as traders navigate broader market uncertainty ahead of the upcoming Federal Reserve interest rate decision.

CleanSpark, Inc. is a bitcoin mining technology company, which engages in the management of data centers. Its operations include College Park, Norcross, Washington, Sandersville, Dalton, and Massena. The company was founded by S. Matthew Schultz and Bryan Huber on October 15, 1987 and is headquartered in Henderson, NV.

Cleanspark Inc

CleanSpark is trending as investors react to a significant Bitcoin price surge and the broader AI data center sector, while debate continues over the company's valuation, high short interest, and the status of its ongoing infrastructure build-outs. Sentiment remains polarized between bulls anticipating a short squeeze or re-rating based on Bitcoin holdings and data center deal potential, and bears expressing frustration over the stock's recent performance compared to its peers.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

The community is debating the significance of the extended timeline for the Phase 3 REGAL trial, with bulls interpreting the delay as evidence of strong patient survival and bears citing it as a negative indicator of efficacy. Despite persistent speculation and criticism from external observers regarding clinical trial timelines, long-term investors remain bullish, often pointing to institutional accumulation and the potential for a strategic buyout as reasons to maintain their positions.

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

Investors are closely monitoring upcoming Starship launch catalysts and potential cross-company integration with Tesla, fueling speculation about future growth and the company's valuation. While some traders remain cautious regarding share lockup expirations and macro volatility, bullish sentiment persists on the company's long-term disruptive potential in space and AI sectors.

Snap, Inc. is a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap is trending following the unveiling of its new Specs AI assistant and augmented reality glasses, with retail sentiment shifting toward bullishness as traders analyze the potential for enterprise applications and long-term tech differentiation. While some investors remain skeptical about the product's high price point and the company's past financial performance, others point to its growing partnerships with major tech firms as a sign of a successful shift in strategy.

Generac Holdings, Inc. engages in the business of designing and manufacturing energy technology solutions. It operates under the Domestic and International segments. The Domestic segment includes the legacy Generac business and the acquisitions that are based in the United States and Canada. The International segment focuses on Generac business' Latin American export operations. The company was founded in 1959 and is headquartered in Waukesha, WI.

Generac Holdings Inc

Generac is trending following a supply agreement with Amazon for backup data center generators that is projected to unlock significant long-term order volume, with analysts responding by raising price targets. The deal has generated significant investor enthusiasm regarding the company's growth as a key player in AI infrastructure, though some market participants have expressed caution regarding potential share dilution from associated warrants.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Verastem is receiving attention following positive clinical update commentary regarding VS-7375, including favorable biomarker data and its potential as a best-in-class KRAS G12D inhibitor. While some traders are optimistic about upcoming data readouts and potential partnership opportunities, others express frustration with the stock's price performance and ongoing concerns regarding potential equity dilution.

Verastem Stock Skyrockets 121% in 3 Months: Here Is Why

VSTM shares surge 121% as Avmapki Fakzynja Co-Pack gains commercial traction and VS-7375 advances across key cancer studies.

Verastem Oncology to Unveil New Clinical Data Highlighting the Best-in-Class Potential of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, Across Pancreatic, Lung, and Colorectal Cancers

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced it will host an investor event on Wednesday, October 14, at 8:00 am ET to present initial efficacy and updated safety and...

Verastem Oncology to Participate in Upcoming September Investor Conferences

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate at the Wells Fargo 21st Annual Healthcare Conference on Sept. 8 in Boston and...

Verastem (VSTM) Reports Q2 Loss, Beats Revenue Estimates

Verastem (VSTM) delivered earnings and revenue surprises of +23.91% and +73.12%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today reported financial results for the second quarter ended June 30, 2026, and highlighted recent business progress. The second quarter marked...

Royalty Pharma (RPRX) Tops Q2 Earnings and Revenue Estimates

Royalty Pharma (RPRX) delivered earnings and revenue surprises of +3.94% and +1.52%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Dianthus Therapeutics, Inc. (DNTH) Reports Q2 Loss, Tops Revenue Estimates

Dianthus Therapeutics, Inc. (DNTH) delivered earnings and revenue surprises of +3.23% and +60.89%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Guardant Health (GH) Reports Q2 Loss, Tops Revenue Estimates

Guardant Health (GH) delivered earnings and revenue surprises of -5.00% and +6.01%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Beats Revenue Estimates

Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of +23.08% and +7.98%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Verastem Oncology Doses First Patient in TARGET-D 203 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Colorectal Cancer

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the first patient has been dosed in the TARGET-D 203 Phase 2 registration-directed trial evaluating VS-7375, an investigational...

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

Verastem Inc

VSTM Stock Climbs After-Hours As FDA Grants Fast Track To Lung Cancer Drug — Retail Eyes The Next Keytruda 

Equity

Neutral Sentiment

A - Strong, decisive leadership

B - Solid, but room to improve

C - Mixed, still figuring it out

D/F - Poor communication and execution

Kevin Warsh has served as Federal Reserve Chair since May 2026, following one of the most divisive Senate confirmations in Fed history, and just delivered the Fed's first rate hike since 2023. How do you grade Kevin Warsh's performance as Fed chair so far? Vote and explain your reasoning in the comments.

Kevin Warsh has been Fed chair since May. How do you grade his performance so far?

Feed

News

Sentiment

Earnings

Fundamentals

Info

VSTM News